pI: 7.345 |
Length (AA): 261 |
MW (Da): 29742 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 1
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 4 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
55 | 139 | 1jr8 (A) | 7 | 101 | 15.00 | 0 | 0.27 | 0.43 | -1.4 |
1 | 183 | 3qcp (A) | 255 | 435 | 60.00 | 0 | 1 | 1.43535 | -0.52 |
52 | 147 | 4e0i (A) | 84 | 183 | 18.00 | 0 | 0.35 | 0.538416 | -1.14 |
57 | 133 | 3gwl (A) | 100 | 185 | 17.00 | 0 | 0.31 | 0.463719 | -1.05 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Ortholog group members (OG5_129038)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G15020 | quiescin-sulfhydryl oxidase 1 |
Arabidopsis thaliana | AT2G01270 | quiescin-sulfhydryl oxidase 2 |
Brugia malayi | Bm1_36435 | Erv1 / Alr family protein |
Caenorhabditis elegans | CELE_F47B7.2 | Protein F47B7.2, isoform B |
Caenorhabditis elegans | CELE_T10H10.2 | Protein T10H10.2 |
Caenorhabditis elegans | CELE_F35G2.1 | Protein F35G2.1, isoform B |
Drosophila melanogaster | Dmel_CG17843 | CG17843 gene product from transcript CG17843-RA |
Drosophila melanogaster | Dmel_CG6690 | CG6690 gene product from transcript CG6690-RA |
Drosophila melanogaster | Dmel_CG4670 | CG4670 gene product from transcript CG4670-RB |
Drosophila melanogaster | Dmel_CG31413 | CG31413 gene product from transcript CG31413-RA |
Echinococcus granulosus | EgrG_000245600 | sulfhydryl oxidase 1 |
Echinococcus multilocularis | EmuJ_000245600 | sulfhydryl oxidase 1 |
Homo sapiens | ENSG00000165661 | quiescin Q6 sulfhydryl oxidase 2 |
Homo sapiens | ENSG00000116260 | quiescin Q6 sulfhydryl oxidase 1 |
Leishmania braziliensis | LbrM.30.0510 | quiescin sulfhydryl oxidase, putative |
Leishmania donovani | LdBPK_300440.1 | quiescin sulfhydryl oxidase, putative |
Leishmania infantum | LinJ.30.0440 | quiescin sulfhydryl oxidase, putative |
Leishmania mexicana | LmxM.29.0430 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_00988 | hypothetical protein |
Loa Loa (eye worm) | LOAG_11834 | Erv1/Alr family protein |
Loa Loa (eye worm) | LOAG_11291 | hypothetical protein |
Mus musculus | ENSMUSG00000033684 | quiescin Q6 sulfhydryl oxidase 1 |
Mus musculus | ENSMUSG00000036327 | quiescin Q6 sulfhydryl oxidase 2 |
Oryza sativa | 4339541 | Os05g0552500 |
Onchocerca volvulus | OVOC2134 | Sulfhydryl oxidase homolog |
Onchocerca volvulus | OVOC4629 | Sulfhydryl oxidase homolog |
Onchocerca volvulus | OVOC3401 | Sulfhydryl oxidase homolog |
Schistosoma japonicum | Sjp_0038080 | ko:K10758 thiol oxidase [EC1.8.3.2], putative |
Schistosoma mansoni | Smp_098710 | quiescin q6-related sulfhydryl oxidase |
Schmidtea mediterranea | mk4.027261.00 | |
Schmidtea mediterranea | mk4.018305.00 | |
Trypanosoma brucei gambiense | Tbg972.6.1550 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.6.1850 | quiescin sulfhydryl oxidase |
Trypanosoma congolense | TcIL3000_0_58190 | quiescin sulfhydryl oxidase |
Trypanosoma congolense | TcIL3000_6_1440 | quiescin sulfhydryl oxidase |
Trypanosoma cruzi | TcCLB.511491.170 | quiescin sulfhydryl oxidase, putative |
Trypanosoma cruzi | TcCLB.511493.10 | quiescin sulfhydryl oxidase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.6.1850 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.6.1850 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.6.1850 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.6.1850 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_F47B7.2 | Caenorhabditis elegans | slow growth | wormbase |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.